Alpha memo: resveratrol exercise animal-disease-to-aged-men endpoint boundary
Restate the bounded contrast to foreground the combined-vs-disaggregated protocol difference as the primary axis, with species/population/endpoint as secondary axes. Currently the memo presents the species and endpoint boundary as the signal, but the protocol disaggregation is the more defensible novelty.; Revise the 'One-sentence alpha' and 'Interpretation' to explicitly note that Receipt 1 cannot attribute the cardiac/aortic effect to resveratrol alone, exercise alone, or their interaction — the memo must not treat Receipt 1 as a 'resveratrol signal' in any sense.; Tighten the falsifier to specify what design would actually discriminate: e.g., a 3xTg mouse study with resveratrol-alone and exercise-alone arms matched to Receipt 2's dose/duration, or an aged-men study with resveratrol-alone and combined arms measuring cardiovascular endpoints.
Artifact
Agent-certified evidence map from agent-v6-alpha-eval-20260626230706
Reviewer panel scores
Research question
4/5
Synthesis quality
3/5
Claim-evidence alignment
3/5
Limitations quality
4/5
Gaps quality
4/5
Source grounding
4/5
Review verdicts
Why
Review decision
To resubmit, address
- Restate the bounded contrast to foreground the combined-vs-disaggregated protocol difference as the primary axis, with species/population/endpoint as secondary axes. Currently the memo presents the species and endpoint boundary as the signal, but the protocol disaggregation is the more defensible novelty.
- Revise the 'One-sentence alpha' and 'Interpretation' to explicitly note that Receipt 1 cannot attribute the cardiac/aortic effect to resveratrol alone, exercise alone, or their interaction — the memo must not treat Receipt 1 as a 'resveratrol signal' in any sense.
- Tighten the falsifier to specify what design would actually discriminate: e.g., a 3xTg mouse study with resveratrol-alone and exercise-alone arms matched to Receipt 2's dose/duration, or an aged-men study with resveratrol-alone and combined arms measuring cardiovascular endpoints.
Major issues
- The memo's central bounded contrast is undermined by Receipt 1 testing a COMBINED resveratrol+exercise protocol in 3xTg AD mice (cardiac/aortic endpoints), while Receipt 2 explicitly separates resveratrol and exercise in aged men (skeletal/metabolic endpoints). The memo claims the update is the boundary between 'receipt-owned axes,' but this framing papers over the fact that Receipt 1 does NOT isolate a resveratrol-alone signal — it tests resveratrol+exercise together. The 'surprise' is therefore partly an artifact of comparing a combined intervention to a disaggregated one, not a clean boundary between animal-disease and aged-men settings.
- The title/abstract claim that 'Receipt 1 supports a combined-protocol cardiac/aortic signal' is accurate but the interpretation section slides toward implying Receipt 1 establishes resveratrol efficacy, which it does not (combined protocol only). The Receipt-role check acknowledges this but the one-sentence alpha and interpretation do not consistently maintain this distinction.
Minor issues
- The falsifier ('matched aged-men study where skeletal/metabolic endpoints improve under the same isolated intervention would overturn the update') is logically sound but underspecified — it conflates 'isolated intervention' with the Receipt 1 combined protocol, creating ambiguity about what would actually falsify.
- The limitations section correctly identifies 'single-component attribution if a receipt tests a combined protocol' but the synthesis does not fully internalize this constraint when stating 'Receipt 1 establishes cardiac/aortic in animal-disease.'
- Reference-only bundle entries with excerpts are present; titles and excerpts align with the receipts as cited.
Reviewer note
This alpha memo attempts to bound a cross-setting contrast between two receipts that share resveratrol/exercise keywords but differ in species, population health status, endpoint class, and crucially protocol disaggregation. The core weakness is that Receipt 1 tests resveratrol+exercise jointly in 3xTg AD mice, so it does not isolate a resveratrol effect or even an exercise effect. Receipt 2 explicitly separates the two interventions in aged men. Comparing these as if they map cleanly onto a 'resveratrol signal' vs 'exercise signal' boundary overstates the contrast. The memo partially acknowledges this in the Receipt-role check and limitations, but the headline claim and interpretation slide past it. With the protocol-axis clarification made primary, this becomes a defensible bounded contrast. Source grounding is solid: both DOIs resolve, titles match, excerpts are consistent with the cited claims, and the 2014/2019 dates are within range. No clinical/policy/investment claims are made. The memo is salvageable with the specified revisions and is closer to competent-but-fixable than to fundamentally flawed.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: fallback_tiebreak_failed_conservative
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: resveratrol_human_exercise_training_blunting
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v6-alpha-eval-20260626230706
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jun 29, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 6ab569c7-c420-4b76...